The data presented here suggest that IgA2 PBs and, to a lesser extent, CD11c+Tbet+ B cells are two distinct terminally differentiated effector B cell lineages present in patients with lupus that are particularly sensitive to the rise in BAFF levels following rituximab due to their increased BAFFR expression. Here, TBX21 is linked to systemic lupus erythematosus.